Abstract:The VHL protein (pVHL) functions as a tumor suppressor by regulating the degradation or activation of protein substrates such as HIF1α and Akt. In human cancers harboring wild-type VHL, the aberrant downregulation of pVHL is frequently detected and critically contributes to tumor progression. However, the underlying mechanism by which the stability of pVHL is deregulated in these cancers remains elusive. Here, we identify cyclin-dependent kinase 1 (CDK1) and peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (PIN1) as two previously uncharacterized regulators of pVHL in multiple types of human cancers harboring wild-type VHL including triple-negative breast cancer (TNBC). PIN1 and CDK1 cooperatively modulate the protein turnover of pVHL, thereby conferring tumor growth, chemotherapeutic resistance and metastasis both in vitro and in vivo. Mechanistically, CDK1 directly phosphorylates pVHL at Ser80, which primes the recognition of pVHL by PIN1. PIN1 then binds to phosphorylated pVHL and facilitates the recruitment of the E3 ligase WSB1, therefore targeting pVHL for ubiquitination and degradation. Furthermore, the genetic ablation or pharmacological inhibition of CDK1 by RO-3306 and PIN1 by all-trans retinoic acid (ATRA), the standard care for Acute Promyelocytic Leukemia could markedly suppress tumor growth, metastasis and sensitize cancer cells to chemotherapeutic drugs in a pVHL dependent manner. The histological analyses show that PIN1 and CDK1 are highly expressed in TNBC samples, which negatively correlate with the expression of pVHL. Taken together, our findings reveal the previous unrecognized tumor-promoting function of CDK1/PIN1 axis through destabilizing pVHL and provide the preclinical evidence that targeting CDK1/PIN1 is an appealing strategy in the treatment of multiple cancers with wild-type VHL.

PIN1 and CDK1 Cooperatively Govern Pvhl Stability and Suppressive Functions

Loss of VHL-mediated pRb regulation promotes clear cell renal cell carcinoma

Pvhl Acts As a Downstream Target of E2F1 to Suppress E2F1 Activity.

WSB1 Promotes Tumor Metastasis by Inducing Pvhl Degradation

VHL suppresses autophagy and tumor growth through PHD1-dependent Beclin1 hydroxylation

VHL loss enhances antitumor immunity by activating the anti-viral DNA-sensing pathway

Long noncoding RNA PVT1 promotes breast cancer proliferation and metastasis by binding miR-128-3p and UPF1

Reciprocal antagonism of PIN1-APC/C CDH1 governs mitotic protein stability and cell cycle entry

Positive feedback regulation of lncRNA PVT1 and HIF2 contributes to clear cell renal cell carcinoma tumorigenesis and metastasis

Positive feedback regulation of lncRNA PVT1 and HIF2α contributes to clear cell renal cell carcinoma tumorigenesis and metastasis

Overexpression of Pin1 regulated by TOP2A, which subsequently stabilizes Pyk2 to promote bortezomib resistance in multiple myeloma

A Positive Feedback Loop between Inactive VHL-Triggered Histone Lactylation and PDGFRβ Signaling Drives Clear Cell Renal Cell Carcinoma Progression

TCTP Increases Stability of Hypoxia‐inducible Factor 1α by Interaction with and Degradation of the Tumour Suppressor VHL

Vhl Inactivation Induces Hef1 and Aurora Kinase A

Data from TBK1 Is a Synthetic Lethal Target in Cancer with <i>VHL</i> Loss

POLR2A Drives Tumor Cell Aggressive in Both VHL and PBRM1 Mutation Renal-Cell Carcinoma

High VHL Expression Reverses Warburg Phenotype and Enhances Immunogenicity in Kidney Tumor Cells

TBK1 is a Synthetic Lethal Target in Cancer with VHL Loss

VBP1 negatively regulates CHIP and selectively inhibits the activity of hypoxia-inducible factor (HIF)-1α but not HIF-2α

VHL suppresses UBE3B-mediated breast tumor growth and metastasis

Phosphorylation-dependent Cleavage Regulates Von Hippel Lindau Proteostasis and Function.